复星医药:积极应对集采,创新药成未来增长重点

新浪财经
Oct 10

投资者提问:仿制药带量集采持续,公司如何通过一致性评价或剂型改良维持市场份额?未来研发是否更聚焦First-in-Class或罕见病领域?董秘回答(复星医药SH600196):投资者您好!公司积极参与药品集采,并通过既有管线和每年新上市产品维持仿制药收入规模,同时通过内部管理、供应链优化和成本控制等举措,减少仿制药利润率的波动。公司坚持创新、国际化战略,未来增长重点在创新药品领域,并聚焦实体瘤、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10